PLK1 and non-small cell lung carcinoma: In line with these results, a large‐scale integrated analysis of Plk1 inhibitor sensitivity showed that NSCLC cell lines with high epithelial–mesenchymal transition gene signature scores were more sensitive to Plk1 inhibitors than epithelial NSCLC cells.